- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018. As quoted in the press release: “Early in 2018, we’ve made notable progress with our immuno-oncology platform as the …
Cellular Biomedicine (NASDAQ:CBMG) a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported financial results and business highlights for the first quarter ended March 31, 2018.
As quoted in the press release:
“Early in 2018, we’ve made notable progress with our immuno-oncology platform as the China Food and Drug Administration (CFDA) accepted the Company’s Investigational New Drug Applications (IND) for “C-CAR011” anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with B-cell Non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL),” commented Tony Liu, Chief Executive Officer of CBMG. “We are advancing recognized CAR-T therapies through China’s regulatory pathway, with our state of the art GMP facility, which houses a CBMG-GE Healthcare China joint innovation center, and a CBMG-Thermo Fisher Scientific joint innovation center.
“The recent investment from Sailing Capital Overseas Investment Ltd., of $30.6 million, will enable further clinical development by funding our current multiple clinical programs, as well as expanding our immuno-oncology pipeline with further CAR-T receptor constructs for various liquid and solid tumor indications, including, but not limited to, Anti-BCMA CAR for multiple myeloma (MM). We continue to focus on accelerating deployment of new cell therapies to the clinical stage, confident in our in-house research and development capabilities, our CMC platform, and our broad clinical development network with leading medical institutions in China.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.